Framework Solutions Acquires UK-based ONIX Life Sciences
Thursday, March 02, 2023
Framework Solutions ("Frameworks"), a provider of clinical to commercial solutions to the life sciences industry, announced today the acquisition of ONIX Life Sciences ("ONIX"). ONIX is a consultancy specializing in regulatory operations services to support life sciences clients. ONIX's global regulatory operations expertise in eCTD Submissions, Publishing, and eCTD Lifecycle Management facilitates client submissions to the FDA, EMA, and other health authorities around the globe. This acquisition helps both companies expand their global reach, while also bolstering service capabilities by providing a broader slate of critical services to clients.
Based in the United Kingdom, ONIX has successfully completed eCTD submissions for more than 100 clients globally (Europe, North America, South America, Middle East, and Asia Pacific). ONIX has never had an eCTD technical rejection and has never missed a deadline since its inception in 2010.
ONIX Founder and CEO, Jasbir Chohan stated, "Frameworks is an industry leader in providing services and technology solutions to the life sciences industry. ONIX prides itself on excellent quality and customer service, a trait that we immediately recognized in the Frameworks team. Combining our Regulatory Operations capabilities alongside Frameworks current offerings will elevate both companies and undoubtedly benefit our customers. We are delighted to partner with the Frameworks team and look forward to supporting life sciences companies as they bring new products to market."
"We are thrilled to welcome Jasbir and the ONIX team to Frameworks," said Joe Walsh, CEO of Frameworks. "ONIX has built an impeccable reputation in the industry and we are excited to bring Regulatory Operations services to our customers. We look forward to working with Jas as we continue to expand our suite of service offerings to best serve the clinical to commercial-stage needs of life sciences clients."
Frameworks, headquartered in Danbury, Connecticut, received a growth investment from WestView Capital Partners in 2021 with the goal of building out end-to-end solutions for clinical and commercial-stage organizations across the life sciences industry. WestView is a Boston-based growth equity firm focused on investing in middle-market companies with a longstanding dedication to the life sciences services sector.
Source: prnewswire.com
